 |
English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12500/13673 (91%)
Visitors : 2803742
Online Users : 525
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/16707
|
| Title: | Reprogramming dysfunctional dendritic cells by a versatile catalytic dual oxide antigen-captured nanosponge for remotely enhancing lung metastasis immunotherapy |
| Authors: | Chiang, MR;Hsu, CW;Pan, WC;Tran, NT;Lee, YS;Chiang, WH;Liu, YC;Chen, YW;Chiou, SH;Hu, SH |
| Contributors: | National Institute of Cancer Research |
| Abstract: | Dendritic cells (DCs) play a crucial role in initiating antitumor immune responses. However, in the tumor environment, dendritic cells often exhibit impaired antigen presentation and adopt an immunosuppressive phenotype, which hinders their function and reduces their ability to efficiently present antigens. Here, a dual catalytic oxide nanosponge (DON) doubling as a remotely boosted catalyst and an inducer of programming DCs to program immune therapy is reported. Intravenous delivery of DON enhances tumor accumulation via the marginated target. At the tumor site, DON incorporates cerium oxide nanozyme (CeO2)-coated iron oxide nanocubes as a peroxide mimicry in cancer cells, promoting sustained ROS generation and depleting intracellular glutathione, i.e., chemodynamic therapy (CDT). Upon high-frequency magnetic field (HFMF) irradiation, CDT accelerates the decomposition of H2O2 and the subsequent production of more reactive oxygen species, known as Kelvin's force laws, which promote the cycle between Fe3+/Fe2+ and Ce3+/Ce4+ in a sustainable active surface. HFMF-boosted catalytic DON promotes tumors to release tumor-associated antigens, including neoantigens and damage-associated molecular patterns. Then, the porous DON acts as an antigen transporter to deliver autologous tumor-associated antigens to program DCs, resulting in sustained immune stimulation. Catalytic DON combined with the immune checkpoint inhibitor (anti-PD1) in lung metastases suppresses tumors and improves survival over 40 days. |
| Date: | 2024-12-31 |
| Relation: | ACS Nano. 2024 Dec 31;19(2):2117-2135. |
| Link to: | http://dx.doi.org/10.1021/acsnano.4c09525 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1936-0851&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:001387073300001 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85215583472 |
| Appears in Collections: | [陳雅雯] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| ISI001387073300001.pdf | | 4976Kb | Adobe PDF | 36 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
